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Erythropoietin (EPO) is a circulating glycoprotein hormone
whose principal function is thought to be red blood cell
production. It is a classic example of a hypoxia-inducible
gene, and studies of the induction of EPO synthesis by low
oxygen led to the discovery of a widespread system of
hypoxia-inducible transcription factors. Tissue-specific
expression of the EPO gene is tightly controlled, and in the
adult organism the kidney produces around 90% of systemic
EPO. Before birth, the liver is the main site of EPO production;
factors contributing to the liver-to-kidney switch are still
elusive, but may provide clues to the tissue-specificity of EPO
gene expression. EPO has also been detected in non-
erythropoietic tissues such as the brain, where it is suggested
to exert local protective effects. Apart from classical ways of
regulating renal EPO during hypoxia and anemia, novel
pathways have been discovered that demonstrate that other
organ systems in the adult might not only be important for
the production of EPO but also for modulating the hypoxic
EPO response. Knowledge of the molecular bases of these
non-renal pathways will eventually help to develop
pharmacological strategies to induce endogenous EPO
production when the main source, the kidney, is significantly
impaired. This review will provide an overview of the
molecular aspects of EPO gene regulation by hypoxia-
inducible transcription factors and of the tissue-specific
regulation of EPO production in adult mammals. Insights into
the biology of EPO production in genetically modified
animals, with an emphasis on recent advances in the
understanding of non-renal EPO regulation, will be discussed.
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REGULATION OF EPO BY HYPOXIA AND HYPOXIA-INDUCIBLE
TRANSCRIPTION FACTORS
That a humoral factor might exist that controls erythropoi-
esis is a concept that dates back more than 100 years. In 1906,
Carnot and Deflandre1 observed a rise in the number of red
blood cells in animals when injected with serum from anemic
donor animals. Before that observation, in 1890, Viault
described the acute effect of hypoxemia on erythropoiesis, in
the first linkage of hypoxia and red blood cell production.
Subsequently, erythropoietin (EPO) was purified in 1977, the
EPO gene was cloned 1985, and the EPO receptor (EPOR)
was cloned in 1989 (see the review by Jelkmann2). Various
studies in vivo showed that EPO mRNA levels could be
induced by orders of magnitude by anemia and subsequent
tissue hypoxia.3 One clue to this oxygen-dependent regula-
tion seemed to be inherent in the structure of the EPO gene:
key regulatory elements, such as the promoter, the first intron
and parts of the 30-flanking region are highly homologous
between species.4 This indicated that both the capability of
certain tissues to express EPO, and the regulation of EPO
gene expression are most likely conserved. As EPO is not
stored, increased production correlates with an increase of
mRNA through increased transcription and increased
stability. Detailed characterization of the 30-regulatory region
of the EPO gene defined it as critical for hypoxic induction5
and led to the identification of the transcription factor,
hypoxia-inducible transcription factor (HIF).6
HIF is a heterodimeric DNA-binding complex
composed of two basic helix-loop-helix proteins of the PAS
family: the constitutive non-oxygen-responsive subunit
HIF-1b (also termed ARNT) and one of either the
hypoxia-inducible a-subunits, HIF-1a or HIF-2a. HIF-a
subunits are rapidly degraded in normoxia but highly
inducible by hypoxia (for review of HIF-a function, see the
review by Wenger7). The interface between oxygen and the
HIF-a subunit is provided by distinct enzymatic reactions:
the hydroxylation of two prolyl residues in the oxygen-
dependent degradation domain of the a-subunits. This
oxygen-dependent hydroxylation regulates the interaction
with the von Hippel–Lindau tumor suppressor protein,
which targets HIF-a for proteolysis by the ubiquitin–protea-
some pathway.8 Under hypoxic conditions, prolyl hydroxyla-
tion is suppressed, HIF-a protein escapes proteasomal
destruction, accumulates, and translocates to the nucleus.
There, the a/b-heterodimeric transactivating complex HIF
binds to promoter or enhancer sequences of target genes that
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control important biological functions, such as glycolysis,
angiogenesis, and erythropoiesis.
The HIF-modifying enzymes are termed prolyl hydro-
xylase domain (PHD) enzymes (PHD1–3) (see the review by
Schofield and Ratcliffe9). The PHDs are nonheme Fe (II) and
2-oxoglutarate-dependent dioxygenases that split molecular
oxygen; thus, in the absence of oxygen, the HIF prolines
remain unmodified. The effects of hypoxia can be mimicked
by iron chelation, use of 2-oxoglutarate analogs, or substitu-
tion of Fe (II) by metal ions, such as cobalt. Therefore,
inhibition of the PHDs represents an attractive target for
pharmacological manipulation of the HIF pathway, as
discussed below.
In contrast to regulation of HIF-a stability by the PHDs,
transcriptional activity is further regulated by the hydroxyla-
tion of an asparagine residue. The hydroxylation reaction is
carried out by an asparaginyl hydroxylase, termed factor
inhibiting HIF (FIH), and this modification prevents interac-
tion of HIF-a with the transcriptional coactivator p300.10
The transcription factors HIF-1a and HIF-2a share
significant sequence homology and are both regulated post-
translationally by protein degradation. HIF-2a, originally
termed endothelial PAS domain protein 1 (EPAS1) because of
its expression in endothelial cells,11 exhibits a more restricted
expression pattern than HIF-1a.12 Although both HIF-a-
subunits are able to bind the consensus HRE, they seem to
regulate a different set of target genes depending on the
cellular context and the oxygen concentration. The factors
and molecular mechanisms that potentially determine this
isoform-specific target gene selectivity remain poorly defined
(see the review by Patel and Simon13). Interestingly, as
discussed below, although HIF-1a was originally identified to
bind to the HRE in the 30-enhancer of the EPO gene,6 there is
now considerable evidence, both in vitro and in vivo, that
HIF-2a is the main HIF-a-subunit controlling EPO gene
expression (Figure 1).
EPO EXPRESSION IN MAMMALIAN TISSUE: RENAL AND
NONRENAL TISSUE
Although far from being completely elucidated, the mechan-
isms underlying the hypoxia-inducible upregulation of the
EPO gene are understood in considerable detail. The
regulatory pathways determining tissue specificity of EPO
expression, however, are much more opaque at this point in
history.
EPO is expressed in the kidney, liver, brain, spleen, lung,
and testis (see the review by Fandrey14). No structural or
functional differences of EPO coming from these different
sources have been described. The kidney is the major site of
EPO production in adult animals. In most patients with
significantly impaired renal function, EPO production is
substantially reduced. Studies in adult rats conducted as early
as 1957 showed that after nephrectomy, plasma EPO levels
decline sharply and can no longer be induced by phlebot-
omy.15 Attempts to identify EPO-producing cells in the
kidney yielded contradictory results initially, but two
important studies provided convincing evidence that the
renal EPO-producing cells are peritubular fibroblast-like
type-1 interstitial cells, located in the renal cortex and outer
medulla.16,17 Immunohistochemical studies indicated that
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Figure 1 | Schematic representation of the EPO gene, its important regulatory sequences, and the factors controlling hypoxic EPO
induction: exons are depicted as red numbered boxes, and UTRs are depicted as open boxes. The kidney-inducible element lies far
upstream (between 9.5 and 14 kb). A negative regulatory element preventing ectopic expression lies nearer, between 6 and 0.4 kb.
The functional GATA site, which has been mapped to the minimal promoter, is expanded. Parts of the 30-liver-inducible element are shown
in detail: the hypoxia response element (HRE) with the HIF-a-binding site (HBS) and the CACA-repeat (HIF ancillary sequence), which is
necessary for full hypoxic induction. The nuclear receptor half-site (DR-2), where hepatic nuclear factor 4 (HNF4) can bind, is adjacent.
The induction of EPO in hypoxia is shown: HIF-2a is stabilized, can dimerize with HIF-1b, and translocates to the nucleus where it binds to
the HRE in the 30-enhancer. P300 is recruited for full activity (and potential interaction with the basal transcriptional machinery in the
minimal promoter). Upper right: in normoxia, HIF-2a is hydroxylated by prolyl hyroxylases (PHD) and thus recognized by von Hippel–Lindau
tumor suppressor protein, which serves as a recognition component of a ubiquitin ligase that targets HIF-a for degradation by the
proteasome. HIF-a is also hydroxylated by factor-inhibiting HIF (FIH), which prevents binding of p300 and reduces transcriptional activity.
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HIF-2a might be the dominant subunit driving hypoxic EPO
expression in these cells.18 Unfortunately, all efforts to
generate EPO-expressing renal cell lines for further detailed
studies have been unsuccessful thus far. Therefore, hepatoma
cell lines are continued to be used to investigate the
molecular bases of EPO regulation. In those cells, HIF-2a
was found to be the HIF-a isoform predominantly
responsible for EPO regulation.19
The kidney is not the only major EPO-producing tissue in
adults (Figure 2); in fact, early estimates indicated that
around 10% of the circulating EPO originates from nonrenal
tissue.20 During fetal development, the main source of EPO is
the liver rather than the kidney. A comprehensive study in
sheep showed that the fetal liver produces the majority of
prenatal EPO and that a liver-to-kidney shift toward renal
EPO production occurs in late gestation.21 This was later
confirmed for other species as well, with differences in the
timing of the onset22 and in the remaining contribution of
the adult liver to the overall EPO production. Efforts to
quantify the contribution of hepatic EPO to the total
production yielded high estimates in rats: around 40%, with
potential to increase the proportion to 80% after nephrect-
omy.23 More intriguing than the actual percentage is the fact
that nonrenal EPO is still produced in a significant amount in
adult mammals. The biological principle behind that
observation, and why extrarenal sites cannot compensate
for the decreased levels of EPO in kidney disease is, however,
still not resolved.
In contrast to the kidney, two hepatic cell types are capable
of producing EPO: hepatocytes and Ito-cells, as determined
by in situ hybridization and the use of transgenic animals.24,25
Another interesting and not yet resolved difference between
renal and hepatic EPO regulation is the fact that hepatocytes
seem to be capable of increasing the EPO expression at a
cellular level, whereas in the kidney, upregulation is achieved
by increased recruitment of a larger number of cells with a
fixed amount of EPO mRNA.24,26
The molecular mechanisms underlying the liver-to-kidney
switch are still obscure. The differential timing between
species, however, suggests that it might not be determined by
physiological changes in circulation or oxygenation during
birth. Studies in transgenic animals containing a copy of the
human EPO gene, including large portions of adjacent
regulatory regions, were performed to identify sequences
necessary for tissue-specific EPO regulation (Figure 1). These
experiments suggested that regulatory elements for hypoxic
induction in the liver are between 0.4 kb upstream and
0.7 kb downstream of the EPO gene-coding sequences. Apart
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Figure 2 | The three main sites of EPO production in mammals: the central nervous system, the liver, and the kidney. In the central
nervous system, EPO produced by astrocytes and neurons is suggested to exert paracrine neuroprotective effects. Controversy exists as to
how much EPO can cross the intact blood–brain barrier in both ways. The majority of the plasma EPO in adult mammals is produced by
interstitial fibroblasts in the kidneys. Renal EPO expression has been shown to be influenced by the hypoxic response of the skin, involving
HIF-1a (rather than HIF-2a) and, during the acute response, HIF-independent pathways. The contribution of the adult liver to the total EPO
production is difficult to quantify: estimates show species differences but can range up to ~ 40% of the total EPO. Hepatic EPO is produced
in Ito-cells and in hepatocytes, where HIF-2a is the main regulator of hypoxic EPO induction. GATA transcription factors have been
described to negatively, but also positively, influence hepatic EPO expression. Novel inhibitory pathways of hepatic EPO expression are
described for VEGF and SUMOylation of HIF-a. Given the central role of HIF in the EPO regulation, targeted pharmacological induction
of HIF through PHD-inhibitors can potentially induce endogenous EPO in the kidney (diseased or healthy) as well as in the two other
nonrenal sites.
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from the HIF-binding site, the 30-enhancer contains a direct
repeat DR-2 element, which is the binding site for nuclear
hormone receptor family members. Hepatic nuclear factor-4
binding to this site is required for full functionality.27
Moreover, a repressing element preventing promiscuous
expression of EPO is present between 0.4 and 6 kb
upstream of the gene28 and an element directing expression
to the kidney lies even further upstream, between 9.5 and
14 kb.29 Specific trans-acting factors or the precise
sequences of the cis-acting elements are, however, still elusive.
Recently, certain GATA transcription factors that bind to a
GATA site in the minimal promoter have been implicated in
the repression of hepatic EPO in vitro and in vivo.30 In
contrast, GATA-4 has been shown to be critical for EPO
transcription in vitro, and expression levels of GATA-4 are
high in fetal liver.31 Tissue-specific expression of different
GATA factors in a defined temporal–spatial pattern might,
therefore, be involved in the liver-to-kidney switch. Taken
together, no clear data exist to date as to why EPO
production is switched from the liver to the kidney, which
factors are involved, and whether this switch is irreversible.
Basal and inducible hepatic EPO production persists after the
switch, although at a much lower amplitude than before. If
extrarenal sources of endogenous EPO are to be exploited in
the future, it will be of great importance to understand the
molecular mechanisms behind this switch in more detail.
The third main tissue known to express EPO and EPOR is
the central nervous system (Figure 2). EPO mRNA is
constitutively expressed in the cortex and hippocampus of
murine and human brains (see the review by Marti32).
On a cellular level, there is evidence that neurons and
astrocytes are the main source of cerebral EPO.33,34 Cerebral
EPO is separated from the systemic circulation by the
blood–brain barrier. It has therefore been suggested that the
physiological role of EPO is not important for erythropoiesis;
however, a contribution of cerebral EPO for other systemic
responses has not been ruled out either. Controversy exists as
to whether recombinant EPO (or endogenous EPO) can
actually cross the intact blood–brain barrier, as suggested by
Brines et al.35 Others have reported that in the absence of
ischemic or traumatic damage, only high does of EPO seem
to be able to cross the adult blood–brain barrier.36 In
summary, although knowledge is still incomplete, the
proposed function of cerebral EPO is more paracrine then
endocrine: it is critical for brain development, acts as an
endogenous protective agent against ischemia and hypoxia,
and as a neurotrophic factor promoting neuronal survival
(see the reviews by Marti32 and Dame et al.37). It is
interesting to note that the EPO production in the brain
seems to be constant, and no significant changes in EPO
expression have been reported for cerebral EPO during
different developmental stages.37 Thus, in contrast to the
liver, putative repressors might act differently in the brain, or
may not exist. As for other putative tissue-specific regulatory
regions: the determinants of continuous CNS EPO expres-
sion remain unknown.
EPO mRNA expression has been detected in the lung,
spleen, testis, and placenta; however, the levels of expression
are low in the lung and spleen.23,38 The role of these organs
for local and systemic EPO homeostasis is therefore still
largely obscure. It is interesting to note, however, that in the
testis, as in the brain, EPO is separated from the systemic
circulation by a blood–testis barrier, potentially obstructing
free diffusion of the hormone and indicating a paracrine role
in this organ as well.
INSIGHTS INTO NONRENAL EPO EXPRESSION BY THE USE OF
GENETICALLY MODIFIED ANIMALS
When kidneys fail to produce substantial levels of EPO, adult
hepatic EPO expression does not compensate for the loss of
renal EPO (for example, as observed in uremic rats23). Thus,
repression of (or the inability to upregulate) the EPO gene in
the adult liver is still dominant even in situations with
increased systemic demand for the hormone after the fetal
liver-to-kidney switch. By elucidating detailed mechanisms of
hepatic EPO gene regulation, researchers seek to find
potential targets for therapeutic intervention.
As pointed out, GATA transcription factors may play a
role in hepatic EPO repression.30 GATA inhibitors have
already been shown to restore erythropoiesis in a mouse
model of anemia of chronic disease,39 but it has not been
shown that these compounds are able to turn on hepatic EPO
synthesis specifically when the kidneys are unable to produce
EPO.
The von Hippel–Lindau gene (VHL), the negative
regulator of both HIF-a isoforms, is frequently mutated in
renal cancer (see the review by Kaelin40). Loss of VHL leads
to HIF-a stabilization, and occasionally to paraneoplastic
polycythemia, due to excessive EPO production of carcino-
matous renal tissue.41 Studies with animals with Cre-loxP-
mediated deletion of VHL in hepatocytes have shown that
chronic inactivation of VHL stabilizes HIF-a and is capable
of overriding hepatic repression of the EPO gene.42
Erythrocytosis was not rescued in double-knockouts of
VHL and HIF1A, suggesting that HIF-2a is a primary
regulator of this effect. This was subsequently shown by the
same group,43 thus the bulk of evidence now suggests that, in
vivo, HIF-2a regulates hepatic hypoxic EPO induction.
Obviously, loss of VHL results in various other pathologies,
some related to HIF-a activation, whereas others are HIF-a
independent. But these studies have shown that through
chronic stimulation of the HIF-a pathway, hepatic EPO
expression was inducible, overriding other potential tissue-
specific repressors. Of note, loss of VHL in a cell type
previously not capable of expressing EPO is not sufficient to
turn on EPO production, as shown in vivo in renal proximal
tubular cells.44 An important complication of the studies
mentioned is the uncertain extent of the described phenotype
caused by the early developmental loss of VHL in
hepatocytes. Therefore, studies with inducible cre-mediated
deletion of VHL in adult mouse hepatocytes are clearly
needed.
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For the kidney, the only published viable global EPAS1
(HIF-2a) knockout mouse suffers from pancytopenia, among
other pathologies; this is the result of reduced renal EPO
production.45 The extent of impairment of hepatic and
cerebral EPO production in those mice was not examined. In
line with hypoxic renal and hepatic EPO induction, the
upregulation of EPO in astrocytes in vitro is also dependent
on HIF-2a.46
NOVEL FINDINGS OF NONRENAL EPO PRODUCTION
Most recent research on EPO expression has focused on the
VHL/HIF-a pathway in EPO-producing tissue. However, the
spectrum of different levels of EPO regulation became
broader recently with several unexpected findings.
An intriguing and unexpected link between the proangio-
genic factor VEGF and hepatic EPO expression was reported
by Tam et al.47 Stringent hepatic and systemic inhibition of
VEGF by various means, as well as conditional deletion of the
VEGF gene in the liver, induced hepatic EPO expression that
increased the hematocrit and led to polycythemia in rodents
and, to a lesser extent, in primates (Figure 2). A VEGF-
dependent repression of hepatocytic EPO was suggested as
the mechanism, which involved sinusoidal endothelial cells
and was potentially mediated by VEGF receptor-2 stimula-
tion. The factors that induce EPO in the absence of VEGF are
still undefined. HIF-1a did not participate as expected;
however, the extent of HIF-2a’s involvement in this novel
pathway remains to be clarified. Intriguingly, deletion of VHL
in hepatocytes increased hepatic VEGF expression,42 but EPO
was still upregulated by HIF-2a stabilization, indicating that
the VHL/HIF-a axis might be dominant over this novel
VEGF-mediated pathway.
A recent report showed yet another level of regulation of
the hepatic EPO expression pathway by linking SUMOylation
and HIF-a. SUMO is a small, ubiquitin-like modifier system
that alters protein–protein interaction. HIF-a can also be
SUMOylated; however, conflicting data exist as to whether
this leads to increased or decreased stability of HIF-a.48,49
SENP1 is a SUMO-specific isopeptidase that removes SUMO
from HIF-1a, and interestingly, SENP1 knockout animals die
in utero due to the lack of hepatic erythropoiesis.49 In this
report, de-SUMOylation seemed to be necessary for full
HIF-a acitivity, with an important role in prenatal hepatic
EPO production. It remains to be determined whether
the SUMO system participates in the tissue-specific regula-
tion of EPO, and whether SUMOylation of HIF-2a is
comparable with that of HIF-1a.
Renal EPO expression can also be influenced by nonrenal
triggers. In work first published in 2005, a humoral factor
released from the brain stem after the increase of cerebral
pressure was postulated to trigger renal EPO expression.50
The identity of this factor is still undetermined. More
recently, the skin was described to play a previously
unappreciated role in oxygen sensing and EPO response
involving HIFs:51 mice with a skin-specific deletion of
HIF1A, but not EPAS1 (HIF-2a), had diminished renal
EPO mRNA induction and reduced systemic plasma EPO
levels after hypoxic exposure. Skin-specific chronic activation
of HIF-a by loss of VHL resulted in increased EPO plasma
levels and polycythemia. No EPO production was detected in
skin, but other HIF-a target genes, such as VEGF and
inducible NO-synthase, were upregulated. The resulting
excessive vasculature and high levels of the vasodilator NO
triggered alterations in blood flow, to an extent such that
hepatic EPO production was induced. Furthermore, by
exposure of the skin of mice to normoxia while breathing
hypoxic air and with pharmacological application of NO
donors to the skin, it was determined that the skin of wild-
type mice has the ability to significantly influence blood flow
during acute and chronic hypoxia, and subsequently alter
systemic EPO response (Figure 2). This novel signaling
pathway established a link between cutaneous oxygen sensing
and the systemic erythropoietic response.
THERAPEUTICAL IMPLICATIONS FOR NONRENAL EPO
EXPRESSION
Emerging novel therapeutical approaches currently under
investigation focus mainly on means to induce endogenous
EPO expression, in contrast to administration of exogenous
recombinant EPO products. Knowledge of the key enzymes
of the oxygen-dependent degradation step of the HIF-a
subunits has directed the focus to compounds that can
inhibit these HIF-a PHDs. Several of such inhibiting
compounds are now available, and animal studies have
established the proof of concept that endogenous
hepatic EPO can be upregulated by pharmacological
stabilization of HIF-a subunits in nephrectomized mice.52
The first human trials using HIF-stabilizing compounds have
been conducted in anephric patients, and have shown that
hepatic EPO can be upregulated in adult human subjects.53
In another subgroup of this study, the diseased kidney
could also be stimulated to produce more EPO. The
same therapeutic principle has also been applied to induce
cerebral EPO in vivo in a model of focal ischemia.54 It has to
be pointed out, however, that tailored substances are
clearly needed, and caution has to be exercised in using
these agents: HIF-a stabilization affects many other pathways
apart from EPO regulation. Several might be desired,
as HIF-a target genes are involved in iron metabolism,55
and thus activation of HIF-a also regulates these factors
synergistically for sustained erythropoiesis. Many other HIF-
a targets have been shown to be protective,56 but others
clearly need to be avoided, as HIF-a signaling is also activated
in neoangiogenesis, cancer, and metastasis (see the review by
Semenza57).
In contrast to the primary therapeutic objective of
inducing hepatic EPO expression, the use of anti-VEGF
antibodies might also potentially enhance hepatic erythro-
poiesis.47 However, no cases of polycythemia under VEGF-
blocking antibody treatment in humans have been reported
so far, possibly because the necessarily high degree of VEGF
blockade is not achieved in clinical settings.
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The observation that the skin plays a role in the systemic
hypoxic response51 indicates that this pathway might be used
therapeutically. Mice treated with NO-donors through the
skin showed an increased EPO response; however, as this is
achieved by blood-flow alterations, dose escalation studies
have to carefully weigh the benefits of this treatment in terms
of stimulation of endogenous erythropoiesis, against the side
effects of NO-donor treatment.
CONCLUSIONS AND OUTLOOK
The regulation of erythropoiesis mainly relies on modulation
of EPO gene expression in response to tissue hypoxia. The
ability to produce substantial amounts of EPO is highly
restricted to certain tissues: the kidney, liver, and brain
(Figure 2). The regulatory network controlling this spectrum
of EPO expression is still incompletely understood: What
precisely are the relative contributions of extrarenal EPO
production, hepatic and potentially cerebral, to the systemic
erythropoietic response? Is hepatic EPO production after the
switch just a developmental artifact, or does it serve an
important physiological purpose? How definite is repression
of EPO expression, and can it be safely reversed and
modulated pharmacologically?
Even if we do not have conclusive answers to these and
other questions raised above, the current understanding of
the diverse pathways influencing EPO gene expression offer
exciting prospects for the future. The liver as a source of
endogenous EPO production for systemic responses is quite
attractive, as studies have shown that this tissue source can be
stimulated pharmacologically by activation of HIF-a. In
the central nervous system, pharmacological upregulation of
endogenous EPO might augment the protective response
during stroke. These are only a few of the therapeutic
approaches imaginable if it becomes feasible to further
specifically direct HIF-a stabilization, and subsequently
target gene induction to nonrenal tissues. It will be intriguing
to see if tailored responses can be achieved that are beneficial
in clinical settings.
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